Empowered Patient Podcast

Dr. Kent Smith, the Chief Executive Officer at Sleep Dallas, raises concerns about the impact of sleep disorders and untreated sleep apnea. He emphasizes that physicians don't always ask patients about the quality of their sleep and that dentists have more time with patients to explore the underlying reasons for inadequate deep sleep.

Kent explains, "I think many in healthcare aren't aware that poor sleep or ineffective sleep or lack of sleep, or unhealthy sleep, can have a severe impact on someone's health. I mean, just cutting the number of hours of sleep can increase cardiovascular disease."

"So then, when you start talking about unhealthy sleep, yes it can lead to diabetes, sudden cardiac death, high blood pressure, depression, and acid reflux. The body needs oxygen. And if the body's not getting oxygen during sleep, then all kinds of bad things can happen."

"I ask every one of my patients, how many hours of sleep do you get? What time do you go to sleep, and what time do you wake up? It's amazing how many only get five or six hours. And it's just routine. And they wonder why they have the health problems they do. So at least we educate them, but I'm afraid sometimes it's too late, and they've already had their first heart attack, or they've already got type two diabetes."

#SleepDallas #SleepPhysicians #SleepApnea #SleepDisorders #APAPDevice #AutoPAP #InspireSolution

sleepdallas.com

Listen to the podcast here

Dr. Kent Smith, the Chief Executive Officer at Sleep Dallas, raises concerns about the impact of sleep disorders and untreated sleep apnea. He emphasizes that physicians don't always ask patients about the quality of their sleep and that dentists have more time with patients to explore the underlying reasons for inadequate deep sleep.

Kent explains, "I think many in healthcare aren't aware that poor sleep or ineffective sleep or lack of sleep, or unhealthy sleep, can have a severe impact on someone's health. I mean, just cutting the number of hours of sleep can increase cardiovascular disease."

"So then, when you start talking about unhealthy sleep, yes it can lead to diabetes, sudden cardiac death, high blood pressure, depression, and acid reflux. The body needs oxygen. And if the body's not getting oxygen during sleep, then all kinds of bad things can happen."

"I ask every one of my patients, how many hours of sleep do you get? What time do you go to sleep, and what time do you wake up? It's amazing how many only get five or six hours. And it's just routine. And they wonder why they have the health problems they do. So at least we educate them, but I'm afraid sometimes it's too late, and they've already had their first heart attack, or they've already got type two diabetes."

#SleepDallas #SleepPhysicians #SleepApnea #SleepDisorders #APAPDevice #AutoPAP #InspireSolution

sleepdallas.com

Download the transcript here

Dr. Tomasz George, Chief Scientific Officer of Virax Biolabs, has developed a novel test process that assesses adaptive immune responses to viruses. This information can inform decisions by patients and doctors on how to most effectively produce an immune response and boost personal protection from the next virus outbreak. An app delivers data about how an individual might respond to a virus and sends notices of specific viruses in a geographic location, along with links to diet and lifestyle suggestions.

Tomasz explains, "We also distribute and sell other viral testing products that look at viruses at different stages of infection and also your immunity at different stages. We intend to provide a subscription service in the next few months that actually allows you to test for these viruses on an ongoing basis, depending on which new viruses are at the moment. And this allows you to determine whether you would expect to cope with these viruses or not if you came in contact with them."

"We have a number of different avenues for selling our tests. We sell direct to consumers because it's a very informative test for people in general population groups. We also are looking to sell to governments, healthcare organizations, and pharma groups who will use our tests in different ways for population health management and management of governmental strategies. And also, for healthcare groups to identify patients who are most at risk and for pharma groups who can help to optimize the population that they study for things like drugs and vaccines by identifying patients who might respond better or worse to specific viruses."

@ViraxBiolabs #ViraxBiolabs #VRAX #ViraxCare #InfectiousDiseases #HealthTech #MedTech #BioTech #RealTimePCRDetection #RTPCR #PCRTest #AntibodyTest #BiomarkerTesting #COVID19

ViraxBiolabs.com

Listen to the podcast here

Dr. Tomasz George, Chief Scientific Officer of Virax Biolabs, has developed a novel test process that assesses adaptive immune responses to viruses. This information can inform decisions by patients and doctors on how to most effectively produce an immune response and boost personal protection from the next virus outbreak. An app delivers data about how an individual might respond to a virus and sends notices of specific viruses in a geographic location, along with links to diet and lifestyle suggestions.

Tomasz explains, "We also distribute and sell other viral testing products that look at viruses at different stages of infection and also your immunity at different stages. We intend to provide a subscription service in the next few months that actually allows you to test for these viruses on an ongoing basis, depending on which new viruses are at the moment. And this allows you to determine whether you would expect to cope with these viruses or not if you came in contact with them."

"We have a number of different avenues for selling our tests. We sell direct to consumers because it's a very informative test for people in general population groups. We also are looking to sell to governments, healthcare organizations, and pharma groups who will use our tests in different ways for population health management and management of governmental strategies. And also, for healthcare groups to identify patients who are most at risk and for pharma groups who can help to optimize the population that they study for things like drugs and vaccines by identifying patients who might respond better or worse to specific viruses."

@ViraxBiolabs #ViraxBiolabs #VRAX #ViraxCare #InfectiousDiseases #HealthTech #MedTech #BioTech #RealTimePCRDetection #RTPCR #PCRTest #AntibodyTest #BiomarkerTesting #COVID19

ViraxBiolabs.com

Download the transcript here

Asaf Zviran is the CEO, CSO, and Co-Founder of C2i Genomics which is both a technology company and a diagnostic company. C2i is providing a decentralized, cloud-based platform that allows global genomic labs, health centers, and pharma companies to do whole-genome sequencing on cancer patient tissue or blood. This technology uses the genomic data to determine the best options for treatment and to monitor treatment response.

Asaf explains, "The way that we look at the cancer detection is in a holistic way. We're actually detecting huge amounts of features across the genome in a very, very sensitive and accurate manner. Many clinical trials have been showing that the C2i whole-genome approach is much more sensitive and accurate than any other technology that is currently in development."

"Whole-genome, I think is a new category in medical genomics in general. Whole-genome allows us to very comprehensively extract everything, all of the variants, all of the genomic changes, in the patient blood. And then the challenge again is how to use this very comprehensive information to create insight, to create applications. This is exactly what C2i is doing. Basically, we are building out clinically validated software applications that can take the whole-genome data, the whole data from the apps that are working with us, and allow very sophisticated AI signal processing to detect cancer, to monitor treatment response, to predict recurrence."

"And we are doing that on a global scale. I can tell you that besides our CLIA-equipped lab in the US, we are working in partnership to deliver these services to other health systems in the US. We are a clinical-approved product in Europe, and starting to do clinical testing and working extensively in Europe. We also have a very strong distribution in the Middle East and Asia. So Israel, Singapore, India, and now going into a new location in Asia."

#C2iGenomics #WholeGenome #WholeGenomeSequencing #PrecisionMedicine #Cancer #Tumors #AI #MedicalGenomics

C2i-Genomics.com

Listen to the podcast here

Asaf Zviran is the CEO, CSO, and Co-Founder of C2i Genomics which is both a technology company and a diagnostic company. C2i is providing a decentralized, cloud-based platform that allows global genomic labs, health centers, and pharma companies to do whole-genome sequencing on cancer patient tissue or blood. This technology uses the genomic data to determine the best options for treatment and to monitor treatment response.

Asaf explains, "The way that we look at the cancer detection is in a holistic way. We're actually detecting huge amounts of features across the genome in a very, very sensitive and accurate manner. Many clinical trials have been showing that the C2i whole-genome approach is much more sensitive and accurate than any other technology that is currently in development."

"Whole-genome, I think is a new category in medical genomics in general. Whole-genome allows us to very comprehensively extract everything, all of the variants, all of the genomic changes, in the patient blood. And then the challenge again is how to use this very comprehensive information to create insight, to create applications. This is exactly what C2i is doing. Basically, we are building out clinically validated software applications that can take the whole-genome data, the whole data from the apps that are working with us, and allow very sophisticated AI signal processing to detect cancer, to monitor treatment response, to predict recurrence."

"And we are doing that on a global scale. I can tell you that besides our CLIA-equipped lab in the US, we are working in partnership to deliver these services to other health systems in the US. We are a clinical-approved product in Europe, and starting to do clinical testing and working extensively in Europe. We also have a very strong distribution in the Middle East and Asia. So Israel, Singapore, India, and now going into a new location in Asia."

#C2iGenomics #WholeGenome #WholeGenomeSequencing #PrecisionMedicine #Cancer #Tumors #AI #MedicalGenomics

C2i-Genomics.com

Download the transcript here

Dr. Noura Abul-Husn is the VP of Genomic Health, and Amy Sturm the Director of Population Health Genomics at 23andMe. With over 13 million customers, 23andMe has built a database that can provide customized and personalized genetic information to individuals that can indicate health predispositions. This kind of information can lead to strategies to reduce the risk of diseases, manage diseases more appropriately, and even prevent diseases.

Noura explains, "Well, 23andMe has been delivering results that could lead to critical healthcare decisions, as you said, for a long time now. And the way people are using that today is typically to bring that information to their trusted healthcare provider to find out what next steps they ought to take based on that information. It could be information that indicates they're at a higher risk for cancer, for example, or for high cholesterol. I think in most cases, we do deliver, from the 23andMe side, information about what that result means for the person, for their health, for their potential risks. And then, they can take action based on that and based on shared decision-making, hopefully, with their healthcare providers."

Amy elaborates, "All doctors want to do the best thing for their patients, but they are honestly limited in many ways. Time, potential lack of reimbursement for having a genetic counseling type conversation, lack of education, and ongoing education to make sure that they are remaining cutting-edge in any genetics or genetics expertise. That's why we're really excited about the acquisition of Lemonade Health to build out genomic healthcare more broadly under 23andMe. As Noura said, 23andMe has been giving back really important health-related genomic risk results for years that really do need to be taken seriously to prevent diseases like heart disease and cancer."

#23andMe #DNATest #GeneticTesting #WelcomeToYou #PrecisionMedicine

23andMe.com

Listen to the podcast here

Dr. Noura Abul-Husn is the VP of Genomic Health, and Amy Sturm the Director of Population Health Genomics at 23andMe. With over 13 million customers, 23andMe has built a database that can provide customized and personalized genetic information to individuals that can indicate health predispositions. This kind of information can lead to strategies to reduce the risk of diseases, manage diseases more appropriately, and even prevent diseases.

Noura explains, "Well, 23andMe has been delivering results that could lead to critical healthcare decisions, as you said, for a long time now. And the way people are using that today is typically to bring that information to their trusted healthcare provider to find out what next steps they ought to take based on that information. It could be information that indicates they're at a higher risk for cancer, for example, or for high cholesterol. I think in most cases, we do deliver, from the 23andMe side, information about what that result means for the person, for their health, for their potential risks. And then, they can take action based on that and based on shared decision-making, hopefully, with their healthcare providers."

Amy elaborates, "All doctors want to do the best thing for their patients, but they are honestly limited in many ways. Time, potential lack of reimbursement for having a genetic counseling type conversation, lack of education, and ongoing education to make sure that they are remaining cutting-edge in any genetics or genetics expertise. That's why we're really excited about the acquisition of Lemonade Health to build out genomic healthcare more broadly under 23andMe. As Noura said, 23andMe has been giving back really important health-related genomic risk results for years that really do need to be taken seriously to prevent diseases like heart disease and cancer."

#23andMe #DNATest #GeneticTesting #WelcomeToYou #PrecisionMedicine

23andMe.com

Download the transcript here

Dr. Jamie Colbert is the Senior Vice President of Care Delivery at Memora Health, a technology company automating manual tasks and administrative functions that take up so much time for healthcare providers. It is creating an environment that promotes interoperability with existing electronic medical record systems and other sources of patient data to improve patient care and provide guidance for patients to self-manage their complex conditions.

Jamie explains, "In terms of the support that patients are receiving, Memora is really helping to provide a lot of additional support that you just couldn't get from having to rely on manual phone calls from your provider's office because providers just don't have the time. The providers are overwhelmed, and they're trying to get through their day and just see the patients that are in front of them in the office. But with Memora, you can automate a lot of those check-ins and support such that you, as a provider team, know that your patients are still well cared for and supported. You don't have to worry about carving out the time during your day to make those phone calls and check in and see how those patients are doing."

"And only those patient questions and symptoms that are concerning would be the ones that would actually go directly to the provider and still require the provider to then message the patient themselves. What we've seen is that it's generally, anywhere from 50% to two-thirds of the patient messages and questions that are coming in today can be safely handled through Memora's AI. And that's a significant burden that's being lifted from providers. When they get home at the end of the day, they're not spending nearly as much time going through all of those messages because Memora was able to answer many of those messages for them."

@MemoraHealth @jcolbertMD #MemoraHealth #CareDelivery #DigitalHealth

memorahealth.com

Listen to the podcast here

Dr. Jamie Colbert is the Senior Vice President of Care Delivery at Memora Health, a technology company automating manual tasks and administrative functions that take up so much time for healthcare providers. It is creating an environment that promotes interoperability with existing electronic medical record systems and other sources of patient data to improve patient care and provide guidance for patients to self-manage their complex conditions.

Jamie explains, "In terms of the support that patients are receiving, Memora is really helping to provide a lot of additional support that you just couldn't get from having to rely on manual phone calls from your provider's office because providers just don't have the time. The providers are overwhelmed, and they're trying to get through their day and just see the patients that are in front of them in the office. But with Memora, you can automate a lot of those check-ins and support such that you, as a provider team, know that your patients are still well cared for and supported. You don't have to worry about carving out the time during your day to make those phone calls and check in and see how those patients are doing."

"And only those patient questions and symptoms that are concerning would be the ones that would actually go directly to the provider and still require the provider to then message the patient themselves. What we've seen is that it's generally, anywhere from 50% to two-thirds of the patient messages and questions that are coming in today can be safely handled through Memora's AI. And that's a significant burden that's being lifted from providers. When they get home at the end of the day, they're not spending nearly as much time going through all of those messages because Memora was able to answer many of those messages for them."

@MemoraHealth @jcolbertMD #MemoraHealth #CareDelivery #DigitalHealth

memorahealth.com

Download the transcript here